Content about Prostate cancer

October 7, 2011
Lilly's Cialis approved for benign prostatic hyperplasia

The Food and Drug Administration has approved a new use for a drug made by Eli Lilly for erectile dysfunction, Lilly said Friday.

INDIANAPOLIS — The Food and Drug Administration has approved a new use for a drug made by Eli Lilly for erectile dysfunction, Lilly said Friday.

The FDA approved Cialis (tadalafil) as a once-daily treatment for men with erectile dysfunction and benign prostatic hyperplasia, also known as BPH, as well as for BPH alone. BPH is a condition in which the prostate enlarges, which can cause urinary symptoms.

October 4, 2011
Study: 3-in-4 cancer patients are vitamin D deficient

More than three-quarters of cancer patients have insufficient levels of vitamin D, and the lowest levels are associated with more advanced cancer, according to a study presented Oct. 2 at the 53rd Annual Meeting of the American Society for Radiation Oncology.

MIAMI BEACH, Fla. — More than three-quarters of cancer patients have insufficient levels of vitamin D, and the lowest levels are associated with more advanced cancer, according to a study presented Oct. 2 at the 53rd Annual Meeting of the American Society for Radiation Oncology.

September 19, 2011
FDA approves two new indications for Amgen's Prolia

The Food and Drug Administration has approved two new uses for a drug made by Amgen, the drug maker said Monday.

THOUSAND OAKS, Calif. — The Food and Drug Administration has approved two new uses for a drug made by Amgen, the drug maker said Monday.

Amgen announced the approval of the biotech drug Prolia (denosumab) for increasing bone mass in men and women who are at risk of fractures due to hormone ablation treatments they are receiving for prostate and breast cancer, respectively.

August 23, 2011
Amgen expects FDA decision on new indication for cancer drug by next April

The Food and Drug Administration will decide whether or not to approve a new usage for a cancer drug made by Amgen by next year, the drug maker said.

THOUSAND OAKS, Calif. — The Food and Drug Administration will decide whether or not to approve a new usage for a cancer drug made by Amgen by next year, the drug maker said.

August 18, 2011
Sun Pharma receives FDA OK for finasteride

Generic drug maker Sun Pharmaceutical Industries has received regulatory approval for a drug designed to treat an enlarged prostate.

MUMBAI, India — Generic drug maker Sun Pharmaceutical Industries has received regulatory approval for a drug designed to treat an enlarged prostate.

According to the Food and Drug Administration's website, Sun Pharma's finasteride tablets in the 5-mg strength were approved on Aug. 16.

Finasteride is the generic equivalent of Proscar and Propecia, which are made by Merck.

August 12, 2011
Mylan ships generic prostate drug

Generic drug maker Mylan has begun shipping a drug for enlarged prostate, the company said Friday.

PITTSBURGH — Generic drug maker Mylan has begun shipping a drug for enlarged prostate, the company said Friday.

Mylan announced the launch of alfuzosin hydrochloride extended-release tablets in the 10-mg strength.

The drug is a generic version of Sanofi's Uroxatral, which had sales of about $241 million during the 12-month period ended in June, according to IMS Health.

July 18, 2011
Safeway raises more than $10.1 million for prostate cancer research

Safeway on Monday announced that its month-long prostate cancer campaign raised nearly $10.1 million as part of the company’s ongoing effort to fund research geared toward finding a cure for the leading cancer affecting men.

PLEASANTON, Calif. — Safeway on Monday announced that its month-long prostate cancer campaign raised nearly $10.1 million as part of the company’s ongoing effort to fund research geared toward finding a cure for the leading cancer affecting men.

June 21, 2011
Watson seeks to commercialize generic Avodart

Watson subsidiary Watson Labs is seeking approval for a drug designed to treat symptomatic benign prostatic hyperplasia in men with an enlarged prostate.

PARSIPPANY, N.J. — Watson subsidiary Watson Labs is seeking approval for a drug designed to treat symptomatic benign prostatic hyperplasia in men with an enlarged prostate.

The company filed an abbreviated new drug application to market dutasteride capsules in the 0.5-mg strength. The drug is a generic version of Avodart, which is made by GlaxoSmithKline.

June 20, 2011
Abbott receives FDA approval for Lupron Depot

The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer.

ABBOTT PARK, Ill. — The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer.

Abbott announced Monday the approval of a 45-mg, six-month formulation of Lupron Depot (leuprolide acetate) for advanced prostate cancer. Previous formulations have allowed patients to receive the drug every month or every three or four months.

June 15, 2011
Urinozinc expands retail distribution to GNC

A dietary supplement that is designed to alleviate the symptoms of an enlarged prostate has arrived at GNC.

MIAMI — A dietary supplement that is designed to alleviate the symptoms of an enlarged prostate has arrived at GNC.

Urinozinc prostate formula now is available at all corporate-owned GNC Live Well stores and at select GNC franchise stores, the company said. Product ingredients for Urinozinc include saw palmetto extract, pumpkin seed, zinc, pygeum africanum, lycopene, magnesium, selenium, folic acid and vitamins B6, B12 and E.

Urinozinc currently is available for purchase at such retail locations as Bi-Lo, Duane Reade, H-E-B, Publix, Rite Aid, Walgreens and Walmart.

June 13, 2011
Study finds possible link between ADT, diabetes

Men with prostate cancer are at a higher risk of developing diabetes or diabetes risk factors if they receive a therapy designed to block the production of testosterone, a new study has suggested.

BOSTON — Men with prostate cancer are at a higher risk of developing diabetes or diabetes risk factors if they receive a therapy designed to block the production of testosterone, a new study has suggested.

June 7, 2011
Safeway announces 11th annual prostate cancer awareness campaign

Safeway once again is raising funds to support prostate cancer research.

PLEASANTON, Calif. — Safeway once again is raising funds to support prostate cancer research.

The retailer said that its month-long annual prostate cancer campaign, now in its 11th year, seeks to raise funds that will be donated to prostate cancer research. Safeway has donated more than $65.4 million to date.

June 2, 2011
Sam's Club celebrates men's health with free screenings

To celebrate Men's Health Month, Sam's Club is offering free men's health screening tests this weekend at select stores, which will be sponsored by Unilever brands, including Dove Men's deodorant and body wash.

BENTONVILLE, Ark. — To celebrate Men's Health Month, Sam's Club is offering free men's health screening tests this weekend at select stores, which will be sponsored by Unilever brands, including Dove Men's deodorant and body wash.

May 18, 2011
Rapaflo reduces CP/CPPS symptoms, improves outcomes among men in mid-stage trial

A branded drug made by Watson Pharmaceuticals reduced symptoms in men with prostate disease, according to results of a mid-stage clinical trial.

WASHINGTON — A branded drug made by Watson Pharmaceuticals reduced symptoms in men with prostate disease, according to results of a mid-stage clinical trial.

Data from the phase-2 study of the drug Rapaflo (silodosin) presented at the American Urological Association’s annual meeting showed that it reduced symptoms and improved outcomes in men with chronic prostatitis/pelvic pain syndrome, also known as CP/CPPS.

May 18, 2011
Study: Xgeva reduces chances of bone metastasis among prostate cancer patients

A cancer drug made by Amgen reduced the chances of prostate cancer spreading to the bones, according to results of a late-stage clinical trial presented at the American Urological Association’s annual meeting in Washington.

THOUSAND OAKS, Calif. — A cancer drug made by Amgen reduced the chances of prostate cancer spreading to the bones, according to results of a late-stage clinical trial presented at the American Urological Association’s annual meeting in Washington.

The phase-3 “Study ‘147” of Xgeva (denosumab) showed that men taking the drug survived for four months longer without the cancer spreading to their bones, compared with those taking placebo.

April 29, 2011
Zytiga OKed as prostate cancer treatment

The Food and Drug Administration has approved a new treatment for prostate cancer made by Johnson & Johnson.

HORSHAM, Pa. — The Food and Drug Administration has approved a new treatment for prostate cancer made by Johnson & Johnson.

Centocor Ortho Biotech, J&J’s biotech subsidiary, announced Thursday the approval of Zytiga (abiraterone acetate), a daily pill for use in combination with the corticosteroid prednisone for treating castration-resistant prostate cancer that has spread to other parts of the body in men who have received prior chemotherapy with Sanofi-Aventis’ Taxotere (docetaxel).

March 24, 2011
GSK no longer will seek approval for Avodart

GlaxoSmithKline withdrew all regulatory approval applications for a drug designed to cut men's risk of developing prostate cancer.

LONDON — GlaxoSmithKline withdrew all regulatory approval applications for a drug designed to cut men's risk of developing prostate cancer.

The drug maker announced it no longer would pursue global approval for Avodart (dutasteride) and would work with regulatory agencies to remove the indication from the product’s license.

March 11, 2011
Dendreon's manufacturing expansion for Provenge OKed

The Food and Drug Administration has approved biotech company Dendreon’s expansion of manufacturing capacity for an immunotherapy treatment for prostate cancer, Dendreon said Thursday.

SEATTLE — The Food and Drug Administration has approved biotech company Dendreon’s expansion of manufacturing capacity for an immunotherapy treatment for prostate cancer, Dendreon said Thursday.

The company said it would be able to increase the ability of Provenge (sipuleucel-T) manufactured at its plant in New Jersey by increasing the number of workstations to produce it from 12 to 48.

The treatment is designed to induce an immune response against prostatic acid phosphatase, an antigen present in most prostate cancers.

March 11, 2011
Sanofi, Regeneron disclose results of phase-3 trial for aflibercept

While failing to improve overall survival, an investigational treatment for non-small cell lung cancer made by Sanofi-Aventis and Regeneron Pharmaceuticals did keep the disease from worsening and, overall, caused patients to respond to treatment, according to results of a late-stage clinical trial.

TARRYTOWN, N.Y. — While failing to improve overall survival, an investigational treatment for non-small cell lung cancer made by Sanofi-Aventis and Regeneron Pharmaceuticals did keep the disease from worsening and, overall, caused patients to respond to treatment, according to results of a late-stage clinical trial.

Sanofi and Regeneron announced Thursday results of the phase-3 “VITAL” trial of aflibercept. Patients were administered either the drug or placebo in addition to docetaxel chemotherapy.

January 27, 2011
GSK receives complete response letter for Avodart

The Food and Drug Administration declined to approve a regulatory approval application from British drug maker GlaxoSmithKline concerning a cancer drug, GSK said Wednesday.

LONDON — The Food and Drug Administration declined to approve a regulatory approval application from British drug maker GlaxoSmithKline concerning a cancer drug, GSK said Wednesday.

GSK said the FDA issued a complete response letter for its application seeking approval for Avodart (dutasteride) to reduce the risk of prostate cancer in men at increased risk of developing the disease. The drug already is approved to treat enlarged prostate.

October 19, 2010
Cardiovascular, diabetes risk associated with prostate cancer drug class

Patients taking a certain class of drugs mostly used for prostate cancer may be at...

SILVER SPRING, Md. Patients taking a certain class of drugs mostly used for prostate cancer may be at higher risk of heart disease and diabetes, the Food and Drug Administration warned on Wednesday.

 

October 3, 2010
Safeway kicks off 10th annual breast cancer awareness initiative

Safeway kicked off its annual breast cancer awareness initiative for the 10th year in a...

September 30, 2010
Study: Jevtana combined with Novantrone reduced death risk in prostate cancer patients

Data published in the latest issue of medical journal The Lancet showed that a recently...

BRIDGEWATER, N.J. Data published in the latest issue of medical journal The Lancet showed that a recently approved drug reduced the risk of death in men with a certain form of prostate cancer by more than a quarter.

 

September 29, 2010
Teva, OncoGenex commence phase-3 trial for advanced prostate cancer drug

Teva Pharmaceutical Industries and OncoGenex Pharmaceuticals have started a late-stage clinical trial of an investigative...

BOTHELL, Wash. Teva Pharmaceutical Industries and OncoGenex Pharmaceuticals have started a late-stage clinical trial of an investigative treatment for advanced prostate cancer, the two companies said Thursday.

 

Teva and OncoGenex, a company based in the Seattle suburb of Bothell, Wash., that develops cancer therapies, announced the start of “SYNERGY,” a phase-3 trial of OGX-011/TV-1011 (custirsen), a first-line therapy for treating castrate-resistant prostate cancer.

 

 

September 28, 2010
FTC looks to debunk health benefit claims made by POM Wonderful in suit

The Federal Trade Commission has sued the maker of a pomegranate juice that touts health...

WASHINGTON The Federal Trade Commission has sued the maker of a pomegranate juice that touts health benefit claims.